Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: normal saline 0.9% Clear all
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 12, 2026, 10:37 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of BLB-201 RSV Vaccine in Infants and Children

NCT05655182
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
Biological · Drug
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
6 Months to 5 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
18
States / cities
La Mesa, California • Modesto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Tocilizumab in Lung Transplantation

NCT06033196
View directory record Official record
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

NCT02967172
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fractures
Interventions
Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 12, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
View directory record Official record
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain

NCT00370994
View directory record Official record
Conditions
Low Back Pain
Interventions
Caudal epidural injection, Percutaneous adhesiolysis
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 12, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239
View directory record Official record
Conditions
Covid19
Interventions
Heterologous stimuli, Neutralization assay
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sleep and Healthy Aging Research on Depression for Younger Women

NCT03848715
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Endotoxin, Placebo
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
25 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 12, 2026, 10:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Terminated Phase 3 Interventional

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

NCT00458276
View directory record Official record
Conditions
Heart Diseases, Hypertension, Pulmonary
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Stanford, California • New York, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 12, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Triptorelin Pamoate, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Early Phase 1 Interventional

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

NCT03777215
View directory record Official record
Conditions
Obesity
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 12, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT01727336
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
Dalantercept and axitinib, Placebo and axitinib
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 12, 2026, 10:37 PM EDT
Terminated Phase 3 Interventional Results available

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

NCT03705962
View directory record Official record
Conditions
Fractures, Open
Interventions
Tobramycin, Placebo: normal saline
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Early Phase 1 Interventional Results available

Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery

NCT04541303
View directory record Official record
Conditions
Postoperative Wound Haemorrhage
Interventions
Tranexamic acid, normal saline
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

NCT01370460
View directory record Official record
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Knee
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 12, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 12, 2026, 10:37 PM EDT